Current and Future Diabetes Blockbusters: Non-injected Insulins- Hype, Hope or Reality?

Introduction

This Brief focuses on current blockbusters in the diabetes market, while identifying the blockbusters of the future, or drugs that are likely to achieve annual global sales greater than $1bn, from the drugs that are currently in development. The companies concerned are placing tremendous efforts into the development of these compounds, to replace current blockbusters as they approach patent expiry. 

Scope

Draws on the 2002 PharmaVitae Brief entitled “The Top 100 Drugs of 2001,” and provides updated sales to H1 2002 

Identifies four key criteria for commercializing promising pipeline drugs to create future star performers 

Three pipeline diabetes drugs are covered: Oralin, AERx, HIM 2 

Forecasts calculated for market growth to 2008 for pipeline drugs 

Report Highlights

BMS has suffered most from patent expiries over 2001-2002, with the loss of metformin in the US 

Non-injected insulin fulfills the greatest unmet need in the diabetes market. Three non-injected candidates, AERx, Oralin, and HIM 2 are vying to be the dominant player 

Eli Lilly and Novo Nordisk are battling for market supremacy in the diabetes market, a battle that will continue with the launch of potential blockbusters in the next three years 

Reasons to Purchase

Access insightful analysis of the most recent dynamics in the diabetes markets with a view to predicting future trends 

Evaluate the critical factors in determining the blockbuster potential of pipeline drugs 

Forecast future sales based on a comprehensive analysis of each product profile 

Publisher: Datamonitor Immune Disorders and Inflammation Rep. 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_Immune_Disorders_and_Inflammation.html#a151